Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis

Circulation

Volumn 85, Issue 2, 1992, Pages 805-815

  Sitko, Gary R ^a   Ramjit, Denise R ^a   Stabilito, Inez I ^a   Lehman, Dale ^a   Lynch, Joseph J ^a   Vlasuk, George P ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Dendreon   (United States)

Author keywords

Factor Xa; Heparin; Thrombin; Tick anticoagulant peptide

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 10A; HEPARIN; HIRUDIN; THROMBIN; TICK ANTICOAGULANT PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; DOG; DRUG EFFICACY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS;

ANIMAL; COMPARATIVE STUDY; CORONARY CIRCULATION; CORONARY DISEASE; DOGS; DRUG SYNERGISM; FACTOR XA; FEMALE; HEMODYNAMICS; HEMOSTASIS; HEPARIN; HIRUDIN; MALE; MYOCARDIAL REPERFUSION; PEPTIDES; RECOMBINANT PROTEINS; RECURRENCE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0026558347     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.85.2.805     Document Type: Article

References (53)

1. Cheseboro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E: Thrombolysis in myocardial infarction (TIMI) trial, phase 1: A comparison between intravenous plasminogen activator and intravenous streptokinase. Circulation 1987;76:142-154
2. Gruppo Italiano per lo Studio della Streptochinasi nell' Infarto Miocardico (GISSI): Long term effects of intravenous thrombolysis in acute myocardial infarction. Lancet 1987;2: 871-874
3. While HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RML, Norris RM: Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after the first myocardial infarction. N Engl J Med 1989; 320:817-821
4. Gruppo Italiano per lo Studio della Soprawivenza a nell' Infarto Miocardico (GISSI-2): A factorial randomized trial of alteplase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71
5. Marder VJ, Sherry S: Thrombolytic therapy: Current status. N Engl J Med 1988;318:1512-1520
6. Topol EJ: Recombinant tissue plasminogen activator: Implication in therapy. Semin Hematol 1989;26:25-31
7. Verstraete M: Thrombolytic treatment in acute myocardial infarction. Circulation 1990;82(suppl II):II-96-II-109
8. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2: 349-360
9. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the Heparin-Aspirin Reperfusion Trial (HART) investigators: A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323:1433-1437
10. Cadroy Y, Harker L: Platelets, thrombosis, and antithrombotic therapies, in Antonaccio M (ed): Cardiovascular Pharmacology, ed 3. New York, Raven Press, Publishers, 1990, pp 515-539
11. Buchanan MR: Mechanisms of pathogenesis of arterial thrombosis: Potential sites of inhibition by therapeutic compounds. Semin Thromb Hemost 1988;14:33-40
12. Miletich JP, Jackson CM, Majerus PW: Properties of the factor Xa binding site on human platelets. J Biol Chem 1978;253:6908-6916
13. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ: Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem 1989;264:17049-17057
14. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S: Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990;76:1-16
15. Fenton JW, Ofosu FA, Moon DG, Maraganone JM: Thrombin structure and function: Why thrombin is the primary target for antithrombotics. Blood Coag Fibrinol 1991;2:69-75
16. Coller BS, Folts JD, Scudder LE, Smith SR: Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986;69:783-786
17. Hanson SR, Pareti FI, Ruggeri RM, Marzee UM, Kunicki TJ, Montgomery RR, Zimmerman RS, Harker LA: Effects of monoclonal antibodies against the platelet glycoprotein IIb/ IIIa receptor complex on thrombosis and hemostasis in the baboon. J Clin Invest 1988;81:149-158
18. Shebuski RJ, Stabilito IJ, Stiko GR, Polokoff MH: Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis. Circulation 1990;82:169-177
19. Fitzgerald DJ, Wright F, Fitzgerald GA: Increased thromboxane biosynthesis during coronary thrombolysis. Circulation 1989;65:83-94
20. Yasuda T, Gold HK, Leinbach RC, Yavitu H, Fallon JT, Gueviero L, Napier MA, Bunting S, Collen D: Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991;83:1038-1047
21. Haskel EJ, Prager NA, Sobel BE, Abendschein DR: Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocelusion. Circulation 1991;83:1048-1056
22. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D: In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990;67:1552-1561
23. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Denny WJ, Bowle EJW, Badimon L, Fuster V: Hirudin, heparin, and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990;82:1476-1484
24. Topol EJ, George BS, Kerelakes DJ, Stump DC, Candela RJ, Abbottsmith CW, Aronson L, Pickel A, Boswick JM, Lee KL, Ellis SG, Califf RM, and the TAMI Study Group: A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-286
25. Hanson SR, Harker LA: Interruption of acute plateletdependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginylchlorometryl ketone. Proc Natl Acad Sci U S A 1988;85:3184-3188
26. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA: Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991;77: 1006-1012
27. Jang IK, Gold HK, Ziskind AA, Leinback RC, Fallon JT, Collen D: Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1990;81:219-225
28. Liu CY, Nossel HL, Kaplan KL: The binding of thrombin by fibrin. J Biol Chem 1979;254:10421-10425
29. Hogg PJ, Jackson CM: Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy. Proc Natl Acad Sci USA 1989;86: 3619-3623
30. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors. J Clin Invest 1990;86: 385-391
31. Bar-Shavit R, Eldor A, Vlodavsky I: Binding of thrombin to subendothelial extracellular matrix: Protection and expression of functional properties. J Clin Invest 1989;84:1096-1104
32. Jordan RE, Farreau LV, Braswell EH, Rosenberg RD: Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem 1982;257:400-405
33. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U: Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984;218: 725-732
34. Mirshahi M, Soria J, Soria C, Falvre R, Lu H, Courney M, Roltsch C, Tripler D, Caen J: Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989;74:1025-1030
35. Gold HK: Conjunctive antithrombotic and thrombolytic therapy for coronary-artery occlusion. N Engl J Med 1990;323: 1483-1485
36. Waxman L, Smith DE, Arcuri KE, Vlasuk GP: Tick anticoagulant peptide is a novel inhibitor of blood coagulation factor Xa. Science 1990;248:593-596
37. Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegl PKS, Vlasuk GP: Characterization of recombinant tick anticoagulant peptide: A highly selective inhibitor of blood coagulation factor Xa. J Biol Chem 1990;265:17746-17752
38. Vlasuk GP, Ramjit D, Fujita T, Dunwiddie CT, Nutt EM, Smith DE, Shebuski RJ: Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991;65:257-262
39. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS: Anticoagulant efficacy of recombinant tick anticoagulant peptide, a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991 84:1741-1748
40. Markwardt F: Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989;15:269-282
41. Stone SR, Hofsteenge J: Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986;25:4622-4628
42. Markwardt G, Fink G, Kaiser B, Klocking HP, Nowak G, Richter M, Sturzebecher J: Pharmacological survey of recombinant hirudin. Pharmazie 1988;43:302-307
43. Marki WE, Wallis RB: The anticoagulant and antithrombotic properties of hirudin. Thromb Haemost 1990;64:344-348
44. Schumacher WA, Lee EC, Lucchesi BR: Augmentation of streptokinase-induced thrombolysis by heparin and prostacyclin. J Cardiovasc Pharmacol 1985;7:739-746
45. Bush LR Shebuski RJ: In vivo models of arterial thrombosis and thrombolysis. FASEB J 1990;4:3087-3098
46. Dodt J, Muller HP, Seemuller U, Chang JY: The complete amino acid sequence of hirudin, a thrombin-specific inhibitor. FEBS Lett 1984;165:180-183
47. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989;86: 7585-7589
48. Prins MH, Hirsh J: Heparin as an adjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991;67:3A-11A
49. Teitel JM, Rosenberg RD: Protection of factor Xa from neutralization by the heparin antithrombin III complex. J Clin Invest 1983;71:1383-1391
50. Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Harker LA: Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1990;82:578-585
51. Gimple LW, Gold HK, Leinbach RC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D: Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989;80:581-588
52. Hemker HC, Beguin S: Mode of action of heparin and related drugs. Semin Thromb Hemost 1991;17(suppl 1):29-34
53. Jordan SP, Waxman L, Smith DE, Vlasuk GP: Tick anticoagulant peptide: Kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990;29: 11095-11100